WCN26-7084 EFFICACY AND SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN HEMODIALYSIS PATIENTS WITH MALIGNANCIES

Read full text Summarise with VIRAT
Authors: Keisuke Morita, Shinya Yamamoto, Kodai Furukawa, Shoko Ohno, Kanae Yamamoto, Ryuichi Hirokawa, Motoko Yanagita, Hideaki Tanaka
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Immune checkpoint inhibitors (ICIs) are novel anticancer agents that modulate the immune system to enhance antitumor immunity. Clinical trials have provided promising efficacy of ICIs to improve the prognosis of patients with advanced malignancies. Pharmacologically, these agents are not primarily excreted via the kidneys; therefore, their use should also be theoretically feasible in patients undergoing maintenance hemodialysis. However, individuals with end-stage renal disease were excluded from clinical trials, limiting understanding of ICIs safety and efficacy in this patient cohort.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Dialysis and Renal Disease Management Renal cell carcinoma treatment

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104169–104169
Publication date
25 March 2026
Language
EN